Mette Nyegaard

Title: Mette Nyegaard: Innovator in CRISPR Gene Therapy

Introduction

Mette Nyegaard is a prominent inventor based in Gistrup, Denmark. She has made significant contributions to the field of gene therapy, particularly in the treatment of fusion gene-related cancers. Her innovative work has the potential to transform cancer treatment and improve patient outcomes.

Latest Patents

Mette Nyegaard holds a patent for her invention titled "CRISPR gene therapy of fusion gene related cancers." This patent describes a composition that includes a first gRNA bound to an RNA-guided endonuclease, forming a first ribonucleoprotein complex. The first gRNA contains a targeting sequence that is complementary to a target sequence in an intron located in the 5' upstream part of a fusion gene. Additionally, a second gRNA is included, which is also bound to an RNA-guided endonuclease, forming a second ribonucleoprotein complex. This second gRNA comprises a targeting sequence that is complementary to a second target sequence in an intron in the 3′ downstream part of the fusion gene. Such compositions may find use in the treatment of fusion gene-related cancers. Mette Nyegaard has 1 patent to her name.

Career Highlights

Mette Nyegaard is affiliated with Aarhus Universitet, where she conducts her research and develops her innovative therapies. Her work is at the forefront of genetic research, focusing on the application of CRISPR technology in oncology.

Collaborations

Mette collaborates with notable colleagues in her field, including Christian Kanstrup Holm and Yonglun Luo. Their combined expertise enhances the research and development of groundbreaking therapies.

Conclusion

Mette Nyegaard is a trailblazer in the field of gene therapy, with her innovative patent addressing critical challenges in cancer treatment. Her contributions are paving the way for future advancements in medical science.